GSK (GSK) announced the U.S. Food and Drug Administration (FDA) has approved Blenrep in combination with bortezomib and dexamethasone for the ...

GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study GMMG-HD7 is an open-label, randomized, multicenter, ...

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) ...

MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM). This is an ASCO Meeting Abstract from the ...